Minneapolis Hematology and Breast Cancer Conference
The Minneapolis Hematology and Breast Cancer Conference, is a CME-accredited, in-person hematology oncology conference featuring leading hematology and breast cancer experts. Expert faculty will place key abstract findings from the 65th ASH Annual Meeting (ASH2023) and the San Antonio Breast Cancer Symposium (SABCS2023) into clinical context and discuss how the results may change the current standards of care for patients with benign and malignant hematologic disorders and breast cancer. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.
This conference allows attendees an opportunity to discuss current research and advances in the field of hematologic disorders and breast cancer with colleagues and key opinion leaders. The goals of this conference are to review and critically assess the results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients.
Target Audience
- Hematologists, Oncologists
- Surgeons
- Radiation Oncologists
- Physician Assistants/Nurse Practitioners
- Pharmacists
- Nurses
ORGANIZING COMMITTEE
Course Director:
Binay Shah, MD, MHA - Binaytara Foundation
Conference Chair:
Shaji Kumar, MD - Mayo Clinic
Roberto Leon Ferre, MD - Mayo Clinic
VENUE INFORMATION
Booking link:
If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $109 per night plus applicable taxes and fees. The cut off date is January 31, 2024:
Learning Objectives
- Review data presented at the ASH2023 and SABCS2023 & discuss their applications in clinical settings.
- Choose new therapeutic options for treating benign and malignant hematologic disorders & breast cancer, understanding appropriate indications and contraindications to these therapeutic approaches.
- Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care in hematology and breast cancer.
- Integrate evolving diagnostic, prognostic, and therapeutic approaches to managing hematologic disorders and breast cancer patients.
- Individualize management of patients based on emerging data from clinical trials and evolving expert guidelines.
GLOBAL ONCOLOGY PROJECT
Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/
DAY 1 - February 23rd, 2024
All times are listed in Central Time (CT)
04:00 PM – 04:45 PM: Registration/Networking & Exhibits
04:45 PM – 05:00 PM: Opening remarks
05:00 PM – 06:45 PM: Session 1
Session Chair: Shaji Kumar, MD
05:00 PM – 05:25 PM: Lymphoma - Patrick Johnston, MD, PhD
05:25 PM – 05:50 PM: Chronic lymphocytic leukemia - Paul Hampel, MD
05:50 PM – 06:15 PM: Multiple myeloma - Joselle Cook, MD
06:15 PM – 06:45 PM: Q & A
06:45 PM – 07:30 PM: Networking/reception & Exhibits
DAY 2 - February 24th, 2024
07:00 AM – 07:55 AM: Breakfast & Exhibits
08:00 AM – 09:30 AM: Session 2
Session Chair: Guru Subramanian Guru Murthy, MD, MS
08:00 AM – 08:25 AM: MDS/Acute Leukemia - Aref Al-Kali, MD
08:25 AM – 08:50 AM: Myeloproliferative neoplasms and CML - Jeremy Allred, MD
08:50 AM – 09:15 AM: Cellular therapy in hematologic malignancies – recent updates - Mithun Shah, MD, PhD
09:15 AM – 09:30 AM: Q & A
09:30 AM – 10:00 AM: Break & exhibits
10:00 AM – 11:30 AM: Session 3 – Case-based discussion
Session Chair: George Rodgers, MD, PhD
Case 1 – Bleeding disorder - Doris Quon, MD, PhD
Case 2 – Clotting disorder - George Rodgers, MD, PhD
Case 3 – ITP/TTP - Meera Sridharan, MD, PhD
Case 4 – Anemia - Meera Sridharan, MD, PhD
Case 5 – Bone marrow failure - Aditi Sharma, MD
11:30 AM - 12:30 PM: Lunch & exhibits
12:30 PM - 02:15 PM: Session 4
Session Chair: Priya Kumar, MD
12:30 PM - 12:55 PM: Hormone receptor-positive breast cancer - Grace Choong, MD
12:55 PM - 01:20 PM: HER2-positive breast cancer - Stuart Bloom, MD, MSc
01:20 PM - 01:45 PM: Triple-negative and HER2 low breast cancer - Roberto Leon-Ferre, MD
01:45 PM – 02:15 PM: Q & A
02:15 PM – 02:30 PM: Break & exhibits
02:30 PM – 04:15 PM: Session 5
Session Chair: Roberto Leon-Ferre, MD
02:30 PM – 02:55 PM: Radiotherapy – best breast practice - Kimberly Corbin, MD
02:55 PM – 03:20 PM: Updates in surgical approach – best breast practice - Jeffrey Johnson, MD
03:20 PM – 03:45 PM: Q & A
03:45 PM – 04:15 PM: Case-based discussion
Case 1 - Ashley Hickman, MD
Case 2 – Considerations in early breast cancer - Applications of recent data - Sarah Premji, MD
Case 3 – Early stage breast cancer - Dhauna Karam, MBBS, MD, FACP
04:15 PM – 04:20 PM: Adjourn
Book hotel room by: Wednesday January 31st to get a discounted rate of $109.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Shaji Kumar, MD
Roberto Leon-Ferre
Guru Subramanian Guru Murthy, MD, MS
Priya Kumar
Siddhartha Yadav, Siddhartha Yadav, MD, FACP
Aref Al-Kali, MD
Jeremy Allred, MD
Anne Blaes, MD MS
Stuart Bloom
Grace Choong
Joselle Cook
Kimberly Corbin
Paul Hampel, M.D.
Jeffrey Johnson
Patrick Johnston, MD/PhD
Roberto Leon-Ferre
Mithun Shah, MD, PhD
Meera Sridharan, MD, PhD; Assistant Professor of medicine and oncology , consultant Division of Hematology, Department of Internal Medicine Rochester, MN
Ashley Hickman, MD
Dhauna Karam, MBBS, MD, FACP
Sarah Premji, MD
Doris Quon, MD, PhD
GEORGE RODGERS, MD, PhD
Aditi Sharma, MD
Available Credit
- 8.25 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 8.25 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 8.25 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.25 Contact Hours.
If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information
Price
POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE:
All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place.
The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference. The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees.
If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.
Violating this policy will result in a fine equivalent to a general display fee for that conference.
If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:
Link to register as an additional rep of a sponsoring company: https://education.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
- If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.